<DOC>
	<DOCNO>NCT00479986</DOCNO>
	<brief_summary>The goal study investigate impact 4 week treatment pioglitazone ( comparison placebo ) biomarkers atherosclerosis cardiovascular risk , well degree activation immune system , give top anti-diabetic treatment ( metformin and/or sulfonylurea drug ) already result good glycemic control .</brief_summary>
	<brief_title>Effects Pioglitazone Type 2 Diabetes Mellitus Coronary Heart Disease</brief_title>
	<detailed_description>PPARgamma activation pioglitazone show associated improvement cardiovascular risk measure clinical ( assessement intima-media-thickness ) biochemical ( hsCRP , MMP-9 etc . ) marker . Well control patient ( HbA1c &lt; 8.0 % ) receive either pioglitazone placebo ( randomise , double-blind ) 4 week . Blood drawn investigate change cardiovascular metabolic marker mRNA isolated circulating mononuclear cell investiagte degree activation immune system , another measure risk atherosclerosis development .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes mellitus stable oral treatment metfromin and/or sulfonylurea age 20 80 year angiographically confirm atherosclerosis hsCRP &gt; 1 mg/l type 1 diabetes HbA1c &gt; 8.5 % severe disease acute coronary syndrome contraindication pioglitazone ( heart failure etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>monocyte activation</keyword>
	<keyword>cardiovascular risk</keyword>
</DOC>